Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

PDE11A Antikörper (C-Term)

PDE11A Reaktivität: Human, Maus, Ratte ELISA, WB, IHC, IF, IP, ICC, CM Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN2747057
  • Target Alle PDE11A Antikörper anzeigen
    PDE11A (phosphodiesterase 11A (PDE11A))
    Bindungsspezifität
    • 12
    • 8
    • 7
    • 6
    • 5
    • 5
    • 5
    • 5
    • 3
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    AA 420-480, C-Term
    Reaktivität
    • 38
    • 25
    • 21
    • 6
    • 6
    • 6
    • 5
    • 4
    • 3
    • 3
    • 3
    • 3
    • 3
    • 2
    • 1
    • 1
    • 1
    Human, Maus, Ratte
    Wirt
    • 40
    • 1
    Kaninchen
    Klonalität
    • 41
    Polyklonal
    Konjugat
    • 18
    • 8
    • 8
    • 3
    • 2
    • 2
    Dieser PDE11A Antikörper ist unkonjugiert
    Applikation
    • 34
    • 31
    • 23
    • 14
    • 11
    • 9
    • 8
    • 4
    ELISA, Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP), Immunocytochemistry (ICC), Confocal Microscopy (CM)
    Aufreinigung
    Affinity Purified
    Immunogen
    Synthetic peptide taken within amino acid region 420-480 on PDE11A protein, common to all PDE11A variants.
    Isotyp
    IgG
    Top Product
    Discover our top product PDE11A Primärantikörper
  • Applikationshinweise
    Optimal working dilution should be determined by the investigator.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    0.69 μg/μL
  • Kelly: "Does phosphodiesterase 11A (PDE11A) hold promise as a future therapeutic target?" in: Current pharmaceutical design, Vol. 21, Issue 3, pp. 389-416, (2015) (PubMed).

    Kelly, Adamowicz, Bove, Hartman, Mariga, Pathak, Reinhart, Romegialli, Kleiman: "Select 3',5'-cyclic nucleotide phosphodiesterases exhibit altered expression in the aged rodent brain." in: Cellular signalling, Vol. 26, Issue 2, pp. 383-97, (2014) (PubMed).

    Hamilton, Hu, Kolomitro, Bell, Maurice, Graham, Siemens: "Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer." in: World journal of urology, Vol. 31, Issue 2, pp. 325-30, (2013) (PubMed).

    Genders, Bradley, Rattigan, Richards: "cGMP phosphodiesterase inhibition improves the vascular and metabolic actions of insulin in skeletal muscle." in: American journal of physiology. Endocrinology and metabolism, Vol. 301, Issue 2, pp. E342-50, (2011) (PubMed).

    Kruse, Møller, Tibaek, Gammeltoft, Olesen, Kruuse: "PDE9A, PDE10A, and PDE11A expression in rat trigeminovascular pain signalling system." in: Brain research, Vol. 1281, pp. 25-34, (2009) (PubMed).

    Baxendale, Fraser: "Mammalian sperm phosphodiesterases and their involvement in receptor-mediated cell signaling important for capacitation." in: Molecular reproduction and development, Vol. 71, Issue 4, pp. 495-508, (2006) (PubMed).

    DAndrea, Qiu, Haynes-Johnson, Bhattacharjee, Kraft, Lundeen: "Expression of PDE11A in normal and malignant human tissues." in: The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, Vol. 53, Issue 7, pp. 895-903, (2005) (PubMed).

  • Target
    PDE11A (phosphodiesterase 11A (PDE11A))
    Andere Bezeichnung
    PDE11A (PDE11A Produkte)
    Synonyme
    PPNAD2 antikoerper, 6330414F14Rik antikoerper, A630086N24Rik antikoerper, Gm350 antikoerper, PDE11A1 antikoerper, si:ch211-222f23.5 antikoerper, PDE11A antikoerper, ppnad2 antikoerper, Pde11a antikoerper, phosphodiesterase 11A antikoerper, phosphodiesterase 11a antikoerper, dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A antikoerper, PDE11A antikoerper, Pde11a antikoerper, pde11a antikoerper, LOC100470038 antikoerper
    UniProt
    Q9HCR9
    Pathways
    cAMP Metabolic Process
Sie sind hier:
Kundenservice